Work

RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: outcomes by EGFR mutation type

Year: 2021

Type: conference-paper

Source: Pneumologie

DOI: 10.1055/s-0041-1723344

Authors: K Nakagawa, E Nadal, E Garon, M Nishio, T Seto, N Yamamoto, K Park, J Y Shih, B Frimodt-Moller, A H Zimmerman, C Visseren-Grul, M Reck

Institutions: Kindai University, Institut Català d'Oncologia, University of California, Los Angeles, The Cancer Institute Hospital, National Hospital Organization Kyushu Cancer Center, Wakayama Medical University Hospital, National Taiwan University Hospital, Eli Lilly (United States), German Center for Lung Research

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4387954594

FWCI:

Cites:

Cited by: 1

Related to: 10